Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2004-07-06
2009-08-11
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C558S194000
Reexamination Certificate
active
07572778
ABSTRACT:
The present invention is related to new derivatives of Combretastatin, of Formulaobtained by total synthesis. The strategy developed for each of the compounds is to i) replace a halogen (i.e. fluorine atom) to hydrogen on olefinic bound; ii) replace an aromatic ring in a natural product with an amino-aromatic ring. Said compounds recognize and bind the tubulin site: are useful for treating pathological states which arise from or are exacerbated by cell proliferation—as anticancer and/or antiangiogenic activity, in a mammal—to pharmaceutical compositions comprising these compounds.
REFERENCES:
patent: 0 731 085 (1996-09-01), None
patent: 02/5007 (2002-06-01), None
Lawrence et al., 2003, CAS: 138:385212.
Tsai's. 1996, CAS: 124:231924.
International Search Report of PCT/IT2004/000375, mailed Apr. 1, 2005.
J. Med. Chem., vol. 35, No. 12, 1992, pp. 2293-2306.
Database Beilstein, Beilstein Institute for Oragnic Chemistry, XP002312832, retrieved from XFIRE, Database accession No. 7965335.
J. Nat. Prod., vol. 63, No. 7, 2000, pp. 969-974.
Bioorg. Med. Chem. Lett., vol. 8, No. 23, 1998, pp. 3371-3374.
J. Med. Chem., vol. 46, No. 16, 2003, pp. 3546-3554.
Bull. Chem. Soc. Jpn., vol. 71, No. 12, 1998, pp. 2903-2922.
Helv. Chim. Acta., vol. 82, No. 12, 1999, pp. 2231-2239.
Hou-Jen Tsai, “Synthesis of Phenyl Substituted Fluoro-Olefins”, Tetrahedron Letters, vol. 37, No. 5, 1996, pp. 629-632, XP002312830.
J. Heterocycl. Chem., vol. 3, 1996, pp. 247-251.
Chem. Pharm. Bull., vol. 40, No. 10, 1992, pp. 2842-2844.
Griggs et al, “Inhibition of Proliferative Retinopathy . . . ”, American Journal of Pathology, vol. 160, No. 3, Mar. 2002.
Cirla et al, “Combretastatins: from natural products to drug discovery”, Nat. Prod. Rep., 2003, 20, 558-564.
Nambu et al, “Combretastatin A-4 Phosphate Suppresses Development . . . ”, Investigative Ophthalmology & Visual Science, Aug. 2003, vol. 44, No. 8.
Nabha et al, “Combretastatin A-4 Prodrug Induces Mitotic . . . ”, Clinical Cancer Research, vol. 8, 2735-2741, Aug. 2002.
Griggs et al, “Combretastatin-A4 Disrupts Neovascular Development . . . ”, British Journal of Cancer (2001) 84(6), 832-835.
Nabha et al, “Preclinical Report Evaluation of Combretastatin A-4 prodrug in a non-Hodgkin's . . . ”, Anti-Cancer Drugs, 2001, 12, pp. 57-63.
Pinney et al, “Synthesis and Biological Evaluation of Aryl Azide Derivatives of Combretastatin A-4 . . . ”, Bioorganic & Medicinal Chemistry 8 (2000) 2417-2425.
Alloatti Domenico
Giannini Giuseppe
Marcellini Marcella
Marzi Mauro
Riccioni Teresa
Nixon & Vanderhye P.C.
Shiao Rei-tsang
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Fluorocombretastatin and derivatives thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorocombretastatin and derivatives thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorocombretastatin and derivatives thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4093531